第二章 对外担保对象的审查 1 第一条 为了保护投资者的合法权益，规范江苏鱼跃医疗设备股份有限公司(以下简称 "公司")的对外担保行为, 有效防范公司对外担保风险, 确保公司资产安全, 根据《中华人民共和国公司法》、《深圳证券交易所上市公司自律监管指引 第 1 号——主板上市公司规范运作》、中国证监会的和证券交易所有关规定 等法律、法规、规范性文件以及《江苏鱼跃医疗设备股份有限公司章程》(以 下简称"《公司章程》"), 结合公司的实际情况, 特制定本制度。 第二条 本制度所称对外担保是指公司为他人提供的担保, 包括公司对控股子公司的 担保。 第三条 公司对外担保实行统一管理, 非经公司董事会或股东会批准, 任何人无权以 公司名义签署对外担保的合同、协议或其他类似的法律文件。 第四条 公司董事和高级管理人员应审慎对待和严格控制担保产生的债务风险, 并对 违规或失当的对外担保产生的损失依法承担连带责任。 第五条 公司控股或实际控制子公司的对外担保, 视同公司行为, 其对外担保应执行 本制度。公司控股子公司应在其董事会或股东会做出决议后及时通知公司履 行有关信息披露义务。 第六条 公司对外担保应当遵循合法、审慎、互 ...

第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规要求，聘任会计师事 务所对公司的财务会计报告发表审计意见、出具审计报告的行为。公司选聘其他审计业务的会 计师事务所，视重要性程度可参照本制度执行。 第三条 公司选聘或解聘会计师事务所应当经董事会审计委员会（以下简称"审计委员会"） 审核同意后，提交董事会审议，并由股东会决定。公司不得在董事会、股东会决定前聘请会计 师事务所开展对公司的财务会计报告审计业务。 江苏鱼跃医疗设备股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为规范江苏鱼跃医疗设备股份有限公司（以下简称"公司"）选聘（含续聘、改聘， 下同）会计师事务所相关行为，提高财务信息质量，切实维护股东利益，根据《中华人民共和 国公司法》《中华人民共和国证券法》《深圳证券交易所股票上市规则》《国有企业、上市公司 选聘会计师事务所管理办法》等有关法律、法规、规章和规范性文件及《江苏鱼跃医疗设备股 份有限公司章程》（以下简称《公司章程》），结合公司实际情况，制定本制度。 第四条 公司控股股东、实际控制人不得在公司董事会、股东会审议前向公司指定会计师 事务所，不得干预审计委员会独立履行审核职责。 ...

董事和高级管理人员持有及买卖本公司股份的专项管理制度 第一章 总 则 公司董事和高级管理人员从事融资融券交易的, 还包括记载在其信 用账户内的本公司股份。 江苏鱼跃医疗设备股份有限公司 第五条 公司股东以及董事和高级管理人员等主体应当遵守法律法规、深圳证 券交易所相关规定以及《公司章程》等规定。 股东以及董事和高级管理人员等主体对持有股份比例、持有期限、变 动方式、变动价格等作出承诺的, 应当严格履行所作出的承诺。 第二章 一般原则和规定 第一条 为加强江苏鱼跃医疗设备股份有限公司(以下简称"公司")对董事和 高级管理人员持有及买卖本公司股份的管理工作, 根据《中华人民共 和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以 下简称"证券法》")、《上市公司董事和高级管理人员所持本公司股份 及其变动管理规则》、《上市公司股东减持股份管理暂行办法》、《深圳 证券交易所上市公司自律监管指引第 10 号——股份变动管理》等法 律法规和中国证券监督管理委员会(以下简称"中国证监会")的有关 规定, 结合公司实际情况, 制定本制度。 第二条 公司及董事和高级管理人员在买卖公司股票及其衍生品种前, 应知悉 ...

关于增加经营范围并修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 为进一步完善公司治理，根据最新修订的《中华人民共和国公司法》（以下简称《公 司法》）《深圳证券交易所股票上市规则（2025 年修订）》《上市公司章程指引（2025 年 修订）》等法律法规、规范性文件的规定，结合公司实际情况，公司拟对《江苏鱼跃医 疗设备股份有限公司章程》（以下简称《公司章程》）中的有关条款进行修订，调整公司 治理架构，由董事会审计委员会行使监事会的职权。同时根据公司经营管理的需要，公 司拟增加经营范围："检验检测服务、特种设备安装改造修理、化妆品批发、化妆品零 售"，公司于 2025 年 11 月 4 日召开了第六届董事会第十三次临时会议按照相关法律法 规对《公司章程》进行修订。 该事项尚需提交 2025 年第二次股东大会审议通过，董事会提请股东大会授权公司 管理层向市场监督管理部门办理增加经营范围及《公司章程》备案等相关手续。 | 序 号 | 更改前 | 更改后 | | --- | --- | --- | | | 第一条为维护江苏鱼跃医疗设备股份有限 | ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-042 江苏鱼跃医疗设备股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 经江苏鱼跃医疗设备股份有限公司（以下简称"鱼跃医疗"或"公司"）第六届董事 会第十三次临时会议提请，公司将于 2025 年 11 月 20 日召开 2025 年第二次临时股东 大会，现就本次股东大会相关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2025 年第二次临时股东大会； 2、股东大会的召集人：董事会； 3、会议召开的合法、合规性：本次股东大会的召开符合《中华人民共和国公司 法》《上市公司股东会规则》等法律、法规、规范性文件及《江苏鱼跃医疗设备股份 有限公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 20 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 20 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券 ...

表决结果：同意：9 票；反对：0 票；弃权：0 票 为进一步完善公司治理，根据最新修订的《中华人民共和国公司法》《深圳证券交 易所股票上市规则（2025 年修订）》《上市公司章程指引（2025 年修订）》等法律法规、 规范性文件的规定，结合公司实际情况，公司拟对《公司章程》中的有关条款进行修订， 调整公司治理结构，由董事会审计委员会行使监事会的职权。同时根据公司经营管理的 需要，公司拟增加经营范围："检验检测服务、特种设备安装改造修理、化妆品批发、 化妆品零售"。 证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-040 江苏鱼跃医疗设备股份有限公司 第六届董事会第十三次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 2025 年 11 月 4 日，江苏鱼跃医疗设备股份有限公司（以下简称"公司"）以通讯表 决的方式召开了第六届董事会第十三次临时会议。公司于 2025 年 10 月 30 日以书面送 达及电子邮件方式向公司全体董事发出了召开公司第六届董事会第十三次临时会议的 通知以及提交审议的议案。会议应出 ...

Core Viewpoint - The company reported its Q3 2025 results, showing a mixed performance with revenue growth but declining net profits, primarily due to increased sales expenses [1] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 6.545 billion, a year-on-year increase of 8.58% - The net profit attributable to shareholders was 1.466 billion, a year-on-year decrease of 4.28% - The non-recurring net profit was 1.169 billion, down 8.21% year-on-year - In Q3 2025, the company recorded revenue of 1.886 billion, up 9.63% year-on-year, but net profit fell by 35.99% to 263 million [1] Expense Analysis - The sales expense ratio for the first three quarters of 2025 was 18.83%, an increase of 3.39 percentage points year-on-year, attributed to enhanced brand building across channels - The management expense ratio was 5.18%, up 0.04 percentage points year-on-year - The R&D expense ratio was 6.79%, an increase of 0.07 percentage points year-on-year - The financial expense ratio was -2.14%, with a slight increase of 0.04 percentage points year-on-year [1] Profitability Metrics - The gross profit margin for the first three quarters of 2025 was 50.35%, a year-on-year increase of 0.22 percentage points - The net profit margin was 22.40%, down 3.04 percentage points year-on-year [1] Product Development and Market Expansion - The respiratory therapy business saw rapid growth in key products, including oxygen machines and ventilators, with ongoing collaboration with Inogen to expand in the U.S. market - The blood glucose management segment launched new products, contributing to significant growth and market share increase - The company is focusing on product innovation and enhancing brand influence to strengthen its market position in blood glucose management [2] International Business Performance - Overseas revenue showed strong growth, particularly in Southeast Asia, with successful market penetration in Thailand and plans to replicate this model in Indonesia and Vietnam - The European market also experienced rapid growth, with respiratory therapy products leading the way - North American revenue increased significantly, supported by deepening strategic cooperation with Inogen - The South American market saw a recovery in Q3, with closer customer relationships being established [3] Revenue and Profit Forecast - Projected revenues for 2025-2027 are 8.537 billion, 9.685 billion, and 10.945 billion, reflecting growth rates of 13% each year - Expected net profits for the same period are 2.005 billion, 2.288 billion, and 2.617 billion, with growth rates of 11%, 14%, and 14% respectively - The current stock price corresponds to PE ratios of 18, 16, and 14 for 2025-2027, with a "buy" rating maintained due to ongoing product upgrades and rapid international expansion [3]

Core Insights - The integration of AI into blood glucose monitors is set to significantly enhance diabetes management for patients, providing a more efficient and user-friendly experience [1][4]. Sales Growth - Sales of Continuous Glucose Monitoring (CGM) devices have seen a remarkable year-on-year growth of over 90% since 2025 on the JD platform [3]. - Yuyue Medical's blood glucose management business has maintained a double-digit growth rate over the past two years [3]. Product Development - Yuyue's new generation CGM device, the Anaitang 5 series, features AI-enhanced algorithms, achieving a Mean Absolute Relative Difference (MARD) value of 8.58%, meeting both clinical and home use standards [4]. - The Anaitang 5 series is the world's first CGM product capable of continuous glucose monitoring for 16 days, with over 13,000 units sold on its launch day, setting an industry record [6]. AI Integration - The collaboration with JD Health has led to the development of a customized CGM device that connects to the JD Health app for AI-driven analysis, offering a comprehensive blood glucose management service [6][11]. - The AI integration allows for proactive health management, providing users with insights based on 100 days of glucose data, and facilitating connections to appropriate healthcare professionals [7]. Market Trends - The healthcare device market is shifting from "passive treatment" to "active prevention," prompting Yuyue to upgrade its traditional products, such as adding atrial fibrillation monitoring to blood pressure monitors [10]. - The demographic of users purchasing medical devices online is increasingly younger, with over 30% of buyers being from the post-90s and post-00s generations [7]. Service Enhancement - Yuyue has established a close collaboration with JD Health, viewing it as a full ecosystem partner to enhance digital healthcare management services [11]. - JD Health's introduction of home nurse services aims to provide professional support for users, enhancing the overall user experience and care [10].

Core Insights - The health consumption market is undergoing a transformation as more individuals shift from "passive treatment" to "active prevention," with blood sugar management becoming a key focus [1] - The CGM (Continuous Glucose Monitoring) devices are gaining popularity, helping diabetes patients avoid painful finger pricks and expanding to broader audiences interested in weight management [1] Group 1: Market Trends - From 2025 onwards, the transaction volume of CGM products on JD.com has seen a year-on-year growth rate exceeding 90% [1] - The increasing adoption of CGM devices is enabling users to monitor blood sugar fluctuations post-meal and create scientifically-based dietary plans [1] Group 2: Company Performance - Yuyue Medical has emerged as a significant player in the home medical device sector, with its blood sugar management business maintaining double-digit growth over the past two years [1] - The newly launched "Anaitang 5 Series" CGM by Yuyue Medical features an AI-enhanced algorithm and a MARD value of 8.58%, achieving international leading accuracy levels [1] Group 3: Product Launch and Sales - The "Anaitang 5 Series" CGM is the first in the world to offer continuous monitoring for 16 days, quickly gaining market traction with over 13,000 units sold on its launch day on JD Health, setting a new industry record [1] - During the 11.11 shopping festival, the sales volume of the Yuyue Anaitang 5 CGM increased by over 100% compared to the previous period, highlighting its market appeal [2] Group 4: Strategic Partnerships - Yuyue Medical views JD Health not just as a sales channel but as a comprehensive ecosystem partner, aiming to enhance the value of its products in blood sugar management [1] - The collaboration has led to the development of a customized CGM device that connects via Bluetooth to the JD Health app, providing a one-stop blood sugar management service [1][2] Group 5: Future Directions - JD Health plans to expand the application of "medical devices + AI" beyond blood sugar management to include blood pressure, ECG, respiration, and sleep monitoring, aiming to create an integrated intelligent health system [2] - The partnership seeks to make quality medical resources more accessible and affordable through a deep integration of hardware, software, services, and ecosystem [2]

Core Insights - The Biotech Index (970038) closed at 2279.35 points, up 0.77%, with a trading volume of 28.709 billion yuan and a turnover rate of 1.85% [1] - Among the index constituents, 41 stocks rose, with Hualan Vaccine leading at a 17.88% increase, while 8 stocks fell, with Deep Technology leading the decline at 6.38% [1] Index Performance - The Biotech Index saw a net inflow of 140 million yuan from institutional investors, while retail investors contributed a net inflow of 210 million yuan, and there was a net outflow of 350 million yuan from speculative funds [1] Top Constituents - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 215.04, and a decrease of 0.76% [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 112.26, and a decrease of 2.55% [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 33.51, and an increase of 1.12% [1] - Other notable constituents include Muyuans (sz002714) and Aimeike (sz300896) with respective weights of 3.66% and 3.44% [1] Capital Flow Details - Detailed capital flow for key stocks includes: - Mindray Medical saw a net inflow of 26.2 million yuan from institutional investors [2] - Muyuans had a net inflow of 203 million yuan from institutional investors [2] - Hualan Vaccine experienced a net inflow of 74.8 million yuan from institutional investors [2]